Diabetes community calls for quality standards for continuous glucose monitoring devices
Year: 2026
Type: article
Abstract: Continuous Glucose Monitoring (CGM) devices are increasingly used by people living with diabetes (PwD) and contribute to a more personalised and effective diabetes care, leading to improved glycaemic control impacting diabetes-related complications. Their use is increasing in Europe, and many new manufacturers are coming to the market. CGMs, tracking in real-time glucose levels, are a key tool for PwD and their healthcare teams in the daily diabetes management. Besides tracking glucose changes in response to food, medication and physical activity, alerts are provided when hypoglycemia or hyperglycemia are imminent, allowing immediate intervention.
Institutions: University of Bari Aldo Moro, University of Ljubljana, Ljubljana University Medical Centre, Scuola Superiore Sant'Anna, King's College London, Innsbruck Medical University, Universität Innsbruck, Ollscoil na Gaillimhe – University of Galway, Centre National de la Recherche Scientifique, Inserm, Université de Montpellier, Centre Hospitalier Universitaire de Montpellier, Institut de Génomique Fonctionnelle, Breakthrough T1D, University of Copenhagen, Steno Diabetes Center Copenhagen, Universitair Ziekenhuis Leuven
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,930
Funders: Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, F. Hoffmann-La Roche, Leona M. and Harry B. Helmsley Charitable Trust, Insulet Corporation, Dexcom, National Institute for Health and Care Research, Diabetes UK, European Commission, European Foundation for the Study of Diabetes, Novo Nordisk, European Association for the Study of Diabetes, Sun Pharma, Roche Diabetes Care, National Institutes of Health, Medical Research Council
OpenAlex ID: W7127320617